A detailed history of Virtus ETF Advisers LLC transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 9,683 shares of ZNTL stock, worth $33,696. This represents 0.02% of its overall portfolio holdings.

Number of Shares
9,683
Previous 9,509 1.83%
Holding current value
$33,696
Previous $38,000 7.89%
% of portfolio
0.02%
Previous 0.02%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.9 - $4.57 $504 - $795
174 Added 1.83%
9,683 $35,000
Q2 2024

Aug 14, 2024

BUY
$4.09 - $16.13 $15,210 - $59,987
3,719 Added 64.23%
9,509 $38,000
Q1 2024

May 15, 2024

SELL
$10.83 - $16.49 $4,321 - $6,579
-399 Reduced 6.45%
5,790 $91,000
Q4 2023

Feb 15, 2024

BUY
$9.84 - $20.13 $21,421 - $43,823
2,177 Added 54.26%
6,189 $93,000
Q3 2023

Nov 07, 2023

SELL
$19.63 - $28.29 $7,910 - $11,400
-403 Reduced 9.13%
4,012 $80,000
Q2 2023

Aug 14, 2023

SELL
$17.41 - $30.05 $11,316 - $19,532
-650 Reduced 12.83%
4,415 $124,000
Q1 2023

May 15, 2023

SELL
$16.14 - $24.94 $31,392 - $48,508
-1,945 Reduced 27.75%
5,065 $87,000
Q4 2022

Feb 14, 2023

BUY
$18.07 - $25.6 $39,591 - $56,089
2,191 Added 45.47%
7,010 $141,000
Q3 2022

Nov 14, 2022

BUY
$20.23 - $31.73 $667 - $1,047
33 Added 0.69%
4,819 $104,000
Q2 2022

Aug 12, 2022

BUY
$17.91 - $52.25 $46,870 - $136,738
2,617 Added 120.65%
4,786 $134,000
Q1 2022

May 16, 2022

SELL
$41.58 - $80.89 $5,654 - $11,001
-136 Reduced 5.9%
2,169 $100,000
Q4 2021

Feb 14, 2022

SELL
$66.92 - $84.79 $99,643 - $126,252
-1,489 Reduced 39.25%
2,305 $194,000
Q3 2021

Nov 15, 2021

SELL
$46.83 - $73.5 $9,272 - $14,553
-198 Reduced 4.96%
3,794 $253,000
Q2 2021

Aug 10, 2021

SELL
$37.41 - $62.25 $68,348 - $113,730
-1,827 Reduced 31.4%
3,992 $212,000
Q1 2021

May 17, 2021

BUY
$35.69 - $52.72 $3,854 - $5,693
108 Added 1.89%
5,819 $252,000
Q4 2020

Feb 12, 2021

BUY
$31.71 - $57.97 $181,095 - $331,066
5,711 New
5,711 $297,000

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $198M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.